羟基喜树碱联合化疗治疗卵巢癌临床剖析.docVIP

羟基喜树碱联合化疗治疗卵巢癌临床剖析 　　[摘要] 目的 探讨羟基喜树碱对卵巢癌的辅助治疗作用及效果。方法 60例晚期卵巢癌患者,随机分为治疗组及对照组,每组30例,术前术后规律化疗,对照组给予标准(CAP)化疗方案,治疗组给予(CAP)+羟基喜树碱化疗方案,对比两组患者术前缓解率,手术切除情况及预后情况。结果 治疗组手术前症状缓解率为86.7%,肿块缩小28mm,手术切除率90.0%,三年生存率40%。对照组中手术前症状缓解率为60.0%,肿块缩小13mm,手术切除率76.7%,三年生存率36.7%,治疗组同对照组间症状缓解率,肿块缩小程度,手术切除率有显著差异。结论 羟基喜树碱辅助治疗卵巢癌,能增加手术的切除率,改善预后,提高疗效。 　　[关键词] 卵巢癌;羟基喜树碱;化疗;预后 　　[中图分类号] R737.31 [中图分类号] A[文章编号] 1673-9701(2009)24-24-02 　　 　　Adjuvant Therapeutic Effect of Hydroxycamptothecin on Ovarian Cancer 　　LI Changhong 　　Department of Gynecology,People’s Hospital of Juye County,Shandong 274900,China 　　 　　[Abstract] Objective To investigate the adjuvant therapeutic effect of hydroxycamptothecin(HCPT) on ovarian cancer. Methods Sixty advanced ovarian cancer patients were randomly divided into experimental group and control group,with 30 patients in each. The patients in both groups received chemotherapy with cyclophosphamide, adriamycin and platinol(CAP), and besides, the patients of experimental group recieved the treatment with HCPT, and the preoperative remission rate and complete resection of tumor and prognosis in patients of two groups were observed. Results The preoperative remission rate of experimental group was 86.7% and the complete resection of tumorwas 90.0%,the tumor diameter showed a 28mm reduction,and a three-year survival rate was 40%,and those of control group were 60%,76.7% and 36.7% and a 13mm reduction,respectively. There was a significant difference in the preoperative remission rate and complete resection of tumor and tumor diameter decrease between the two groups. ConclusionChemotherapy with HCPT as an adjuvant therapy in ovarian cancer can obtain good therapeutic efficacy,elevate the surgical resection rate and improve prognosis,raising therapeutic efficacy. 　　[Key Words] Ovarian cancer;Hydroxycamptothecin;Chemotherapy; Prognosis 　　 　　卵巢癌是妇科常见恶性肿瘤,发病率约占女性恶性肿瘤的5%。卵巢癌缺乏特异性症状,早期诊断困难,超过半数病人临床确诊时已经为晚期,部分病人临床确诊后原发肿瘤已无法切除,应用术前化疗,可达到减小肿瘤病灶目的,使晚期肿瘤病人获得手术切除机会,术后应用化疗能够明显改